CN105324395A - 治疗急性肾损伤的方法 - Google Patents

治疗急性肾损伤的方法 Download PDF

Info

Publication number
CN105324395A
CN105324395A CN201480011012.2A CN201480011012A CN105324395A CN 105324395 A CN105324395 A CN 105324395A CN 201480011012 A CN201480011012 A CN 201480011012A CN 105324395 A CN105324395 A CN 105324395A
Authority
CN
China
Prior art keywords
kidney
injury
experimenter
acute
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480011012.2A
Other languages
English (en)
Chinese (zh)
Inventor
R.A.扎格
D.安德烈斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Fred Hutchinson Cancer Center
Original Assignee
AbbVie Inc
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Fred Hutchinson Cancer Center filed Critical AbbVie Inc
Publication of CN105324395A publication Critical patent/CN105324395A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480011012.2A 2013-03-08 2014-03-10 治疗急性肾损伤的方法 Pending CN105324395A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775174P 2013-03-08 2013-03-08
US61/775174 2013-03-08
PCT/US2014/022688 WO2014138738A1 (en) 2013-03-08 2014-03-10 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
CN105324395A true CN105324395A (zh) 2016-02-10

Family

ID=51492045

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480011012.2A Pending CN105324395A (zh) 2013-03-08 2014-03-10 治疗急性肾损伤的方法

Country Status (10)

Country Link
US (1) US20160015701A1 (enExample)
EP (1) EP2964671A4 (enExample)
JP (1) JP2016512201A (enExample)
CN (1) CN105324395A (enExample)
AU (1) AU2014225320A1 (enExample)
BR (1) BR112015020788A2 (enExample)
CA (1) CA2901922A1 (enExample)
HK (1) HK1220209A1 (enExample)
MX (1) MX2015011730A (enExample)
WO (1) WO2014138738A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789117A (zh) * 2016-10-05 2019-05-21 米托布里奇公司 治疗急性肾损伤的方法
CN113272013A (zh) * 2019-12-17 2021-08-17 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
CN115005157A (zh) * 2022-06-02 2022-09-06 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
CN115279402A (zh) * 2019-11-06 2022-11-01 西北大学 对ve-ptp磷酸酶的抑制保护肾免于缺血-再灌注损伤
US12582631B2 (en) 2022-08-16 2026-03-24 Chinook Therapeutics, Inc. Methods of improving renal function

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909871A1 (en) 2013-04-30 2014-11-06 Abbvie Inc. Methods for improving lipid profiles using atrasentan
MX2017005884A (es) * 2014-11-07 2017-06-26 Abbvie Inc Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
KR102177349B1 (ko) * 2018-02-13 2020-11-12 서울대학교병원 체세포 복제 효율 증진용 조성물
US10978176B2 (en) 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
CN113209111A (zh) * 2021-05-14 2021-08-06 上海海糖生物医药科技有限公司 一种褐藻寡糖的应用
CN116731117B (zh) * 2023-06-19 2024-05-10 武汉大学 Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100743A1 (en) * 2004-04-23 2006-05-11 Renal Diagnostic Inc. Automated non-invasive real-time acute renal failure detection system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US20110319333A1 (en) * 2010-06-24 2011-12-29 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100743A1 (en) * 2004-04-23 2006-05-11 Renal Diagnostic Inc. Automated non-invasive real-time acute renal failure detection system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US20110319333A1 (en) * 2010-06-24 2011-12-29 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S GULMEN等: "Tezosentan Reduces the Renal Injury Induced by Abdominal Aortic Ischemia-Reperfusion in Rats", 《JOURNAL OF SUGRICAL RESEARCH》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789117A (zh) * 2016-10-05 2019-05-21 米托布里奇公司 治疗急性肾损伤的方法
CN109789117B (zh) * 2016-10-05 2022-08-23 米托布里奇公司 治疗急性肾损伤的方法
CN115279402A (zh) * 2019-11-06 2022-11-01 西北大学 对ve-ptp磷酸酶的抑制保护肾免于缺血-再灌注损伤
US12121509B2 (en) 2019-12-17 2024-10-22 Chinook Therapeutics, Inc. Methods of improving renal function
US11491137B2 (en) 2019-12-17 2022-11-08 Chinook Therapeutics, Inc. Methods of improving renal function
CN116327758A (zh) * 2019-12-17 2023-06-27 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
US11998526B2 (en) 2019-12-17 2024-06-04 Chinook Therapeutics, Inc. Methods of improving renal function
CN113272013A (zh) * 2019-12-17 2021-08-17 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
US12370174B2 (en) 2019-12-17 2025-07-29 Chinook Therapeutics, Inc. Methods of improving renal function
US12521369B2 (en) 2019-12-17 2026-01-13 Chinook Therapeutics, Inc. Methods of improving renal function
CN115005157A (zh) * 2022-06-02 2022-09-06 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
CN115005157B (zh) * 2022-06-02 2023-12-26 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
US12582631B2 (en) 2022-08-16 2026-03-24 Chinook Therapeutics, Inc. Methods of improving renal function

Also Published As

Publication number Publication date
AU2014225320A1 (en) 2015-08-06
BR112015020788A2 (pt) 2017-10-10
EP2964671A1 (en) 2016-01-13
WO2014138738A1 (en) 2014-09-12
WO2014138738A8 (en) 2015-12-30
EP2964671A4 (en) 2016-08-31
CA2901922A1 (en) 2014-09-12
JP2016512201A (ja) 2016-04-25
HK1220209A1 (zh) 2017-04-28
US20160015701A1 (en) 2016-01-21
MX2015011730A (es) 2016-04-04

Similar Documents

Publication Publication Date Title
CN105324395A (zh) 治疗急性肾损伤的方法
Ataga et al. The nephropathy of sickle cell trait and sickle cell disease
Katagiri et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition
Mohammed et al. Contrast-induced nephropathy
Dumoulin et al. Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC
Bachorzewska-Gajewska et al. Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?
Perazella et al. New drug toxicities in the onco-nephrology world
Bachorzewska-Gajewska et al. NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine
JP6822412B2 (ja) 妊娠高血圧腎症のための診断アッセイ及び治療
US9572787B2 (en) Inhibition of renal fibrosis
JP2011221033A (ja) 早発型の腎尿細管細胞障害を検出するための方法およびキット
Worcester et al. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I
You et al. Podocyte-specific chemokine (CC motif) receptor 2 overexpression mediates diabetic renal injury in mice
CN105939728A (zh) 用于治疗和预防肾病和脂肪肝病的方法
Ogura et al. Potential amelioration of upregulated renal HIF-1alpha–endothelin-1 system by landiolol hydrochloride in a rat model of endotoxemia
Wang et al. Spontaneous one-kidney rats are more susceptible to develop hypertension by DOCA-NaCl and subsequent kidney injury compared with uninephrectomized rats
Ando et al. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Feng et al. Avian erythroblastosis virus E26 oncogene homolog-1 (ETS-1) plays a role in renal microvascular pathophysiology in the Dahl salt-sensitive rat
US20210095293A1 (en) Methods of treating cancers with gpr132 inhibitors
CN103429242A (zh) 用于预防和治疗心脏肥大的方法和组合物
JP6679096B2 (ja) Ｒａｇｅアプタマーおよびその用途
Vijay et al. Autosomal dominant polycystic kidney disease: a comprehensive review
JP2020518633A5 (enExample)
KR20230107866A (ko) Btk 억제제를 사용한 전신성 홍반성 루푸스의 치료 방법
CN116887843A (zh) 用于降低接受维持性透析的患者中的草酸盐/酯水平的组合物和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160210